Jacob M Estes, Charles A Leath, J Michael Straughn, Rodney P Rocconi, Tyler O Kirby, Warner K Huh, Mack N Barnes
BACKGROUND: Our goal was to determine the morbidity, disease-free survival, and overall survival of patients with bowel resection at primary cytoreductive surgery for advanced epithelial ovarian carcinoma in the era of platinum and taxane chemotherapy. STUDY DESIGN: We performed a retrospective study of patients undergoing bowel resection at the time of primary cytoreduction for advanced epithelial ovarian carcinoma, who subsequently received platinum and taxane chemotherapy, from 1996 to 2001...
October 2006: Journal of the American College of Surgeons